Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4382 - Thermal Liquid Biopsy as a Valuable Tool in Lung Cancer Screening Programs


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site

Thoracic Malignancies


Alberto Rodrigo


Annals of Oncology (2019) 30 (suppl_5): v574-v584. 10.1093/annonc/mdz257


A. Rodrigo1, S. Vega2, J. Ojeda Cabrera2, O. Sanchez-Gracia2, A. Callejo3, A. Fernandez4, P. Iranzo3, M. Cruellas Lapena4, E. Quilez Bielsa5, A. Velazquez-Campoy6, O. Abian7, D. Isla4

Author affiliations

  • 1 Dept. Medical Oncology, Hospital Universitario Arnau de Vilanova, 25198 - Lleida/ES
  • 2 University Of Zaragoza, Instituto BIFI, Zaragoza/ES
  • 3 Medical Oncology, Vall d'Hebron Institute of Oncology and University Hospital, 08019 - Barcelona/ES
  • 4 Medical Oncology, Hospital Clinico Universitario Lozano Blesa, 50009 - Zaragoza/ES
  • 5 Medical Oncology, Hospital Clínico Universitario Lozano Blesa, Zaragoza/ES
  • 6 University Of Zaragoza, ARAID foundation, Zaragoza/ES
  • 7 University Of Zaragoza, IACS-ISS Aragón, Zaragoza/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4382


Implementing screening programs for risk populations can reduce lung cancer mortality by detecting the disease at early stages, when surgical intervention or chemotherapy treatment can be conducted with best prognosis. Screening protocols based on Low-Dose CT presents a series of drawbacks and needs complementary methods for improving sensitivity and specificity in the screening procedure. Thermal Liquid Biopsy (TLB) is as a complementary technique that, combined with imaging techniques, may improve the efficacy of the screening method.


Blood samples from Healthy Controls (HC) and Lung Cancer Patients (LCP) were analyzed with a high sensitivity microcalorimeter VP-DSC (MicroCal – Malvern Panalytical). The data were processed in Origin 7.0 software. The plasma thermograms were analyzed through a multiparametric method developed by our research group. Statistical models allowed classifying the subjects according their serum thermograms.


115 LCP subjects (average age 64.6±8.7, 83.0% men) with broad stage distribution (II: 5%, III: 26%; IV: 69%), smoking status (64% smoking, 7% non-smoking), histology distribution (37% adenocarcinoma, 29% squamous, 30% small cell) were compared to 119 HC subjects homogeneously distributed from a blood bank. TLB parameters obtained showed statistical differences between HC and LCP groups. Different statistical models were applied in order to establish the optimal TLB output, which is able to classify subjects according to their TLB thermogram: 92% success rate, 90% specificity, and 94% sensitivity (i.e., diagnostic odds ratio of 140).


High positive association between clinical groups and TLB multiparametric model offers advantages over current diagnosis techniques (LDCT imaging), providing a powerful diagnostic approach with a minimally-invasive, low-risk, low-cost clinical test for LCP. Future promising applications, such as screening programs, could be developed from TLB.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Instituto Carlos III (Spain).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.